drugset / Trial / NCT06908642

Evaluation the Safety of hemay005 Tablets

NCT06908642

Phase 1 Completed 468 enrolled Anhui Hemay Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

Timeline

Start
2024-12-25
Primary completion
2025-06-03
Completion
2025-06-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator MUFEMILAST Small molecule 45 mg
Comparator MUFEMILAST Small molecule 60 mg
Comparator MUFEMILAST Small molecule 75 mg